Recently Released Market Study: Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
GlobalData has released its new PharmaPoint Drug Evaluation report, "Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022". Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases...
View full press release